These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

722 related articles for article (PubMed ID: 25760296)

  • 1. Towards a stratified targeted approach with biologic treatments in rheumatoid arthritis: role of synovial pathobiology.
    Astorri E; Nerviani A; Bombardieri M; Pitzalis C
    Curr Pharm Des; 2015; 21(17):2216-24. PubMed ID: 25760296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biologic therapy for rheumatoid arthritis: clinical efficacy and predictors of response.
    Gibbons LJ; Hyrich KL
    BioDrugs; 2009; 23(2):111-24. PubMed ID: 19489652
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biomarkers in Rheumatoid Arthritis, what is new?
    Gavrilă BI; Ciofu C; Stoica V
    J Med Life; 2016; 9(2):144-8. PubMed ID: 27453744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab versus tocilizumab in anti-TNF inadequate responder patients with rheumatoid arthritis (R4RA): 16-week outcomes of a stratified, biopsy-driven, multicentre, open-label, phase 4 randomised controlled trial.
    Humby F; Durez P; Buch MH; Lewis MJ; Rizvi H; Rivellese F; Nerviani A; Giorli G; Mahto A; Montecucco C; Lauwerys B; Ng N; Ho P; Bombardieri M; Romão VC; Verschueren P; Kelly S; Sainaghi PP; Gendi N; Dasgupta B; Cauli A; Reynolds P; Cañete JD; Moots R; Taylor PC; Edwards CJ; Isaacs J; Sasieni P; Choy E; Pitzalis C;
    Lancet; 2021 Jan; 397(10271):305-317. PubMed ID: 33485455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stratification of biological therapies by pathobiology in biologic-naive patients with rheumatoid arthritis (STRAP and STRAP-EU): two parallel, open-label, biopsy-driven, randomised trials.
    Rivellese F; Nerviani A; Giorli G; Warren L; Jaworska E; Bombardieri M; Lewis MJ; Humby F; Pratt AG; Filer A; Gendi N; Cauli A; Choy E; McInnes I; Durez P; Edwards CJ; Buch MH; Gremese E; Taylor PC; Ng N; Cañete JD; Raizada S; McKay ND; Jadon D; Sainaghi PP; Stratton R; Ehrenstein MR; Ho P; Pereira JP; Dasgupta B; Gorman C; Galloway J; Chinoy H; van der Heijde D; Sasieni P; Barton A; Pitzalis C;
    Lancet Rheumatol; 2023 Nov; 5(11):e648-e659. PubMed ID: 38251532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.
    Dennis G; Holweg CT; Kummerfeld SK; Choy DF; Setiadi AF; Hackney JA; Haverty PM; Gilbert H; Lin WY; Diehl L; Fischer S; Song A; Musselman D; Klearman M; Gabay C; Kavanaugh A; Endres J; Fox DA; Martin F; Townsend MJ
    Arthritis Res Ther; 2014; 16(2):R90. PubMed ID: 25167216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bilateral evaluation of the hand and wrist in untreated early inflammatory arthritis: a comparative study of ultrasonography and magnetic resonance imaging.
    Navalho M; Resende C; Rodrigues AM; Pereira da Silva JA; Fonseca JE; Campos J; Canhão H
    J Rheumatol; 2013 Aug; 40(8):1282-92. PubMed ID: 23729806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic agents in rheumatoid arthritis: an update for managed care professionals.
    Agarwal SK
    J Manag Care Pharm; 2011; 17(9 Suppl B):S14-8. PubMed ID: 22073935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synovial Immunophenotype and Anti-Citrullinated Peptide Antibodies in Rheumatoid Arthritis Patients: Relationship to Treatment Response and Radiologic Prognosis.
    Orr C; Najm A; Biniecka M; McGarry T; Ng CT; Young F; Fearon U; Veale DJ
    Arthritis Rheumatol; 2017 Nov; 69(11):2114-2123. PubMed ID: 28732135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Are rheumatoid arthritis patients discernible from other early arthritis patients using 1.5T extremity magnetic resonance imaging? a large cross-sectional study.
    Stomp W; Krabben A; van der Heijde D; Huizinga TW; Bloem JL; van der Helm-van Mil AH; Reijnierse M
    J Rheumatol; 2014 Aug; 41(8):1630-7. PubMed ID: 25028382
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Th17 and CD24
    Salomon S; Guignant C; Morel P; Flahaut G; Brault C; Gourguechon C; Fardellone P; Marolleau JP; Gubler B; Goëb V
    Arthritis Res Ther; 2017 Feb; 19(1):33. PubMed ID: 28183330
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between an expanded autoantibody profile and treatment responses to biologic therapies in patients with rheumatoid arthritis.
    Petro AD; Dougherty J; England BR; Sayles H; Duryee MJ; Hunter CD; Kremer JM; Pappas DA; Robinson WH; Curtis JR; Thiele GM; Mikuls TR
    Int Immunopharmacol; 2021 Feb; 91():107260. PubMed ID: 33360371
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rheumatoid arthritis: Biological therapy other than anti-TNF.
    Rossi D; Modena V; Sciascia S; Roccatello D
    Int Immunopharmacol; 2015 Aug; 27(2):185-8. PubMed ID: 25840282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Value of ultrasonography as a marker of early response to abatacept in patients with rheumatoid arthritis and an inadequate response to methotrexate: results from the APPRAISE study.
    D'Agostino MA; Wakefield RJ; Berner-Hammer H; Vittecoq O; Filippou G; Balint P; Möller I; Iagnocco A; Naredo E; Østergaard M; Boers M; Gaillez C; Van Holder K; Le Bars M;
    Ann Rheum Dis; 2016 Oct; 75(10):1763-9. PubMed ID: 26590174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of anti-citrullinated protein antibody reactivities in an inception cohort of patients with rheumatoid arthritis receiving treat-to-target therapy.
    Jonsson MK; Hensvold AH; Hansson M; Aga AB; Sexton J; Mathsson-Alm L; Cornillet M; Serre G; Lillegraven S; Fevang BS; Catrina AI; Haavardsholm EA
    Arthritis Res Ther; 2018 Jul; 20(1):146. PubMed ID: 30001740
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-grade synovitis associates with clinical markers and response to therapy in chronic inflammatory arthritis:
    Garaffoni C; Tamussin M; Calciolari I; Lanza G; Bortoluzzi A; Scirè CA; Govoni M; Silvagni E
    Front Immunol; 2023; 14():1298583. PubMed ID: 38274811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytokinin panel in rheumatoid arthritis and correlation with histological patterns of synovitis -- active type of disease.
    Avrămescu C; Vere CC; Mărgăritescu C; Turculeanu A; Bălăşoiu M; Rogoz S
    Rom J Morphol Embryol; 2005; 46(2):87-92. PubMed ID: 16286991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Active foot synovitis in patients with rheumatoid arthritis: applying clinical criteria for disease activity and remission may result in underestimation of foot joint involvement.
    Wechalekar MD; Lester S; Proudman SM; Cleland LG; Whittle SL; Rischmueller M; Hill CL
    Arthritis Rheum; 2012 May; 64(5):1316-22. PubMed ID: 22135142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Angiogenic cytokines can reflect the synovitis severity and treatment response to biologics in rheumatoid arthritis.
    Kim JW; Kong JS; Lee S; Yoo SA; Koh JH; Jin J; Kim WU
    Exp Mol Med; 2020 May; 52(5):843-853. PubMed ID: 32461558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor: a systematic review and economic evaluation.
    Malottki K; Barton P; Tsourapas A; Uthman AO; Liu Z; Routh K; Connock M; Jobanputra P; Moore D; Fry-Smith A; Chen YF
    Health Technol Assess; 2011 Mar; 15(14):1-278. PubMed ID: 21439251
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.